Acquiring Company
GSK plc
Acquired Company
35Pharma
MontrealManufacturingBiotechnologyHealth CarePharmaceuticalBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
On February 25, 2026, GSK plc announced its agreement to acquire 35Pharma, a clinical-stage biopharmaceutical company. This acquisition includes HS235, an investigational medicine for pulmonary hypertension. The partnership aims to accelerate the development of HS235 and enhance treatment options for PH patients.
Other recent acquisitions in Pharmaceutical and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Eli Lilly to acquire Centessa Pharmaceuticals (March 31, 2026)
- Aurinia acquires Kezar Life Sciences for $6.955/share (March 30, 2026)
- Servier Pharmaceuticals to acquire Day One Biopharma (March 11, 2026)
- Kopran Limited to merge with Kopran Laboratories Limited (February 27, 2026)
- Alkermes acquires Avadel Pharmaceuticals for growth (February 25, 2026)
- Garda Therapeutics to acquire Assertio for $125.1M, $125M (April 8, 2026)
Who to call at GSK plc, and when
When GSK plc changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day GSK plc raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at GSK plc, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at GSK plc. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment GSK plc makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired 35Pharma?
35Pharma was acquired by GSK plc. The deal was reported on February 25, 2026. GSK plc is a global healthcare company that researches and develops innovative pharmaceutical products, including vaccines. GSK plc is publicly traded (GSK) and operates in Manufacturing.
When did GSK plc acquire 35Pharma?
GSK plc's acquisition of 35Pharma was reported on February 25, 2026. On February 25, 2026, GSK plc announced its agreement to acquire 35Pharma, a clinical-stage biopharmaceutical company. This acquisition includes HS235, an investigational medicine for pulmonary hypertension. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does 35Pharma do?
35Pharma is a private, clinical-stage biopharmaceutical company. It specializes in developing novel protein-based therapeutics for treating cardiopulmonary diseases. It is privately held, operating in Biotechnology, and is based in Montreal.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.